Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) closed at $34.02 in the last session, up 1.61% from day before closing price of $33.48. In other words, the price has increased by $1.61 from its previous closing price. On the day, 0.78 million shares were traded. NAMS stock price reached its highest trading level at $34.695 during the session, while it also had its lowest trading level at $33.6.
Ratios:
We take a closer look at NAMS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 12.57 and its Current Ratio is at 12.57. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On August 25, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $45.
On July 17, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $27.Goldman initiated its Neutral rating on July 17, 2025, with a $27 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 06 ’26 when Douglas F Kling bought 300,000 shares for $33.48 per share.
Louise Kooij bought 2,647 shares of NAMS for $88,012 on Jan 05 ’26. On Jan 05 ’26, another insider, Johannes Kastelein, who serves as the Affiliate of the company, bought 6,000 shares for $33.25 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 3857554944 and an Enterprise Value of 3154875136. For the stock, the TTM Price-to-Sale (P/S) ratio is 109.47 while its Price-to-Book (P/B) ratio in mrq is 5.29. Its current Enterprise Value per Revenue stands at 89.518 whereas that against EBITDA is -15.563.
Stock Price History:
The Beta on a monthly basis for NAMS is 0.07, which has changed by 0.31037188 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $42.00, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is -7.54%, while the 200-Day Moving Average is calculated to be 29.47%.
Shares Statistics:
According to the various share statistics, NAMS traded on average about 1.10M shares per day over the past 3-months and 699090 shares per day over the past 10 days. A total of 113.17M shares are outstanding, with a floating share count of 80.55M. Insiders hold about 28.96% of the company’s shares, while institutions hold 67.16% stake in the company. Shares short for NAMS as of 1765756800 were 6258439 with a Short Ratio of 5.67, compared to 1763078400 on 6817112. Therefore, it implies a Short% of Shares Outstanding of 6258439 and a Short% of Float of 6.5799996.
Earnings Estimates
A detailed examination of NewAmsterdam Pharma Company NV (NAMS) is currently in progress, with 13.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.31 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.01 and -$1.58 for the fiscal current year, implying an average EPS of -$1.34. EPS for the following year is -$1.5, with 11.0 analysts recommending between -$1.15 and -$2.08.
Revenue Estimates
A total of 14 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $45.34M, while the lowest revenue estimate was $19.13M, resulting in an average revenue estimate of $23.42M. In the same quarter a year ago, actual revenue was $43.39M
